Chromocell Therapeutics Corp (CHRO)

NYSEAMERICAN: CHRO · IEX Real-Time Price · USD
1.990
+0.170 (9.34%)
At close: Apr 17, 2024, 4:00 PM
1.600
-0.390 (-19.60%)
Pre-market: Apr 18, 2024, 5:24 AM EDT
9.34%
Market Cap 11.48M
Revenue (ttm) n/a
Net Income (ttm) -7.38M
Shares Out 5.77M
EPS (ttm) -5.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,312
Open 1.830
Previous Close 1.820
Day's Range 1.820 - 2.040
52-Week Range 1.610 - 6.000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date May 20, 2024

About CHRO

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Je... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 16, 2024
Employees 3
Stock Exchange NYSEAMERICAN
Ticker Symbol CHRO
Full Company Profile

Financial Performance

Financial Statements

News

Chromocell Issues Letter to Stockholders from Chief Executive Officer

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatmen...

8 days ago - GlobeNewsWire

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ther...

27 days ago - GlobeNewsWire

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment ther...

4 weeks ago - GlobeNewsWire

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment thera...

5 weeks ago - GlobeNewsWire

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a ...

7 weeks ago - GlobeNewsWire

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on de...

2 months ago - GlobeNewsWire

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and ...

2 months ago - GlobeNewsWire

Chromocell Therapeutics Files for IPO

Chromocell Therapeutics Corp. filed for an initial public offering with the U.S. Securities and Exchange Commission on Wednesday.

1 year ago - MarketWatch

Chromocell Therapeutics IPO Registration Document (S-1)

Chromocell Therapeutics has filed to go public with an IPO on the Nasdaq.

1 year ago - SEC